Abstract
Oral, but not transdermal, estrogen therapy increases the risk of venous thromboembolism (VTE) in women who are past menopause. Data from the Estrogen and Thromboembolism Risk (ESTHER) study were used to investigate the effects of the genetic polymorphism of NFE2L2 rs6721961, which may impair Nrf2-dependent hepatic conjugation of estrogen metabolites. As compared with nonusers, the odds ratio (OR) for VTE in current users of oral estrogens was 2.5 (95% confidence interval (CI): 1.3-4.8) in patients with wild-type NFE2L2 and 17.9 (95% CI: 3.7-85.7) in those with the polymorphism (interaction, P = 0.01).
Publication types
-
Comparative Study
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Cutaneous
-
Administration, Oral
-
Aged
-
Case-Control Studies
-
Estradiol / administration & dosage
-
Estradiol / adverse effects
-
Estradiol / pharmacokinetics
-
Estradiol / therapeutic use
-
Estrogen Replacement Therapy / adverse effects*
-
Estrogens / administration & dosage
-
Estrogens / adverse effects
-
Estrogens / pharmacokinetics
-
Estrogens / therapeutic use
-
Female
-
Genetic Association Studies
-
Humans
-
Metabolic Detoxication, Phase II / genetics
-
Middle Aged
-
NF-E2-Related Factor 2 / genetics*
-
Odds Ratio
-
Polymorphism, Single Nucleotide*
-
Postmenopause*
-
Pulmonary Embolism / epidemiology
-
Pulmonary Embolism / genetics
-
Risk Factors
-
Venous Thromboembolism / epidemiology
-
Venous Thromboembolism / genetics*
-
Venous Thrombosis / epidemiology
-
Venous Thrombosis / genetics
Substances
-
Estrogens
-
NF-E2-Related Factor 2
-
NFE2L2 protein, human
-
Estradiol